Author:
Svensson Kjell A.,Heinz Beverly A.,Schaus John M.,Beck James P.,Hao Junliang,Krushinski Joseph H.,Reinhard Matthew R.,Cohen Michael P.,Hellman Sarah L.,Getman Brian G.,Wang Xushan,Menezes Michelle M.,Maren Deanna L.,Falcone Julie F.,Anderson Wesley H.,Wright Rebecca A.,Morin S. Michelle,Knopp Kelly L.,Adams Benjamin L.,Rogovoy Borys,Okun Ilya,Suter Todd M.,Statnick Michael A.,Gehlert Donald R.,Nelson David L.,Lucaites Virginia L.,Emkey Renee,DeLapp Neil W.,Wiernicki Todd R.,Cramer Jeffrey W.,Yang Charles R.,Bruns Robert F.
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference31 articles.
1. Arnsten AFT Girgis RR Gray DL Mailman RB (2016) Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry, in press, DOI: 10.1016/j.biopsych.2015.12.028.
2. IV. Benzodiazepine pharmacology of cultured mammalian CNS neurons
3. Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM and Woldfangel CD (2014) inventors, Eli Lilly and Company, assignee. 3,4-dihydroisoquinolin-2(1H)-yl compounds. International patent WO 2014/193781 A1. 2014 May 5.
4. The Physiology, Signaling, and Pharmacology of Dopamine Receptors
5. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes;Bruns;Mol Pharmacol,1990
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献